Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.56 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.56 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28301176 | 0.85 | MAPK1 (0.62) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL11005634 | 0.84 | KCNMA1 (0.66) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL8430862 | 0.83 | MAPK1 (0.61) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL116971 | 0.83 | MAPK1 (0.65) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL28299521 | 0.83 | MAPK1 (0.61) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL9210909 | 0.83 | MAPK1 (0.61) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL28300949 | 0.83 | MAPK1 (0.61) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL5606246 | 0.83 | KCNMA1 (0.64) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL16739563 | 0.81 | KCNMA1 (0.63) | MAPK1MAPTALDH1A1KCNMA1PKM | |
| SCHEMBL11459145 | 0.81 | KCNMA1 (0.67) | MAPK1MAPTALDH1A1KCNMA1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7488744-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2009-02-10 | — | — | US | disclosed |
| US-20070232617-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS, INC. (US) | 2007-10-04 | — | — | US | disclosed |
| US-7220763-B2 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2006112828-A1 | AZAINDOLE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
| EP-1551807-A4 | IMPROVED REAGENTS FOR N-AMINATION | SCIOS INC (US) | 2006-09-13 | — | — | EP | disclosed |
| EP-1545528-A4 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | SCIOS INC. | 2005-12-29 | — | — | US | disclosed |
| EP-1551807-A1 | IMPROVED REAGENTS FOR N-AMINATION | SCIOS INC. (US) | 2005-07-13 | — | — | EP | disclosed |
| EP-1545528-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | SCIOS INC. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050065344-A1 | Phenyl hydroxylamines containing one nitro and at least one trifluoromethyl substituent on the phenyl moiety; amination of indole | SCIOS, INC. | 2005-03-24 | — | — | US | disclosed |
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | SCIOS, INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004022712-A2 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF p38 KINASE | SCIOS INC. (US) | 2004-03-18 | — | — | WO | disclosed |
| WO-2004007462-A1 | IMPROVED REAGENTS FOR N-AMINATION | SCIOS INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142940-A1 | Indole-type derivatives as inhibitors of p38 kinase | MAPK1, MAPKAPK2, MAPK4 | MAPK1 1/4885MAPT 1076/4885ALDH1A1 2371/4885 |
| US-20070232617-A1 | INDOLE-TYPE DERIVATIVES AS INHIBITORS OF P38 KINASE | MAPK1, MAPKAPK2, MAPKAPK5 | MAPK1 1/4885MAPT 936/4885ALDH1A1 1773/4885 |
| US-20050288299-A1 | Azaindole derivatives as inhibitors of p38 kinase | MAPKAPK2, MAPK1, MAPK3 | MAPK1 2/4885MAPT 1615/4885ALDH1A1 1498/4885 |
| US-20050065344-A1 | Phenyl hydroxylamines containing one nitro and at least one trifluoromethyl substituent on the phenyl moiety; amination of indole | NAT1, PNMT, HTR3A | MAPK1 2207/4885MAPT 2905/4885ALDH1A1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.